Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
SAOL looking good guysss. Germanzz got into it...Should fly sooon..
Its almost forming a CUP pattern ...all it has to do is go up tomorrow and it should finish the cup nicely !!!
WWEN Shakerzzzz..GUYZZZ Looooks Good at this point.
Should have a good run very soooon...
I might jump aboard tomorrow.
If NTRZ was the only stock I owned what can I do??
I think U are upset that I posted the same stock pick on different Boards??
Am I correct
CXIA...Earnings coming out on SUNDAY...
Be ready for a BOOM
CXIA....Earnings Coming out on SUNDAY!!
CXIA: Awarded Remediation Demonstration Contract From the Department of Energy's Office of Environmental Management
Monday , August 14, 2006 11:42 ET
Commodore Applied Technologies, Inc. (CXIA) announced that the Company's wholly owned subsidiary, Commodore Advanced Sciences, Inc., has been awarded an Advanced Remediation Demonstration contract by the Department of Energy's Office of Environmental Management (DOE-EM) for the Company's technology for the separation of radioactive (surrogate) and RCRA heavy metals from sludges and other waste matrices.
The DOE-EM awarded 12 contracts totaling $3.3 million to support the development of technologies that have the potential to reduce cleanup costs and increase the safety and efficiency of treating and disposing of various waste streams, including radioactive waste at such sites as Hanford, Idaho, Savannah River, and others.
CASI's Phase I contract will be performed over a six month period. Phase I proposed activities include: laboratory/pilot-scale test results, developing a technical approach for demonstration, scale-up and implementation schedule, detailed system design, and a detailed cost estimate for implementation in Phase II.
http://www.jmdutton.com/research/ntrz/notes/ntrz_note_081706.pdf
NTRZ...ShakerZZZZZZZZZZ Get in for the GAP..
Dutton confirmed strong Buy..target is 100% up from here....
Heavy Buying goning onnnn
Company Reports Record Net Income of $.01 Per Share
Aug. 15 /PRNewswire-FirstCall/ -- NutraCea (OTC Bulletin Board: NTRZ), a world leader in stabilized rice bran research and technology, announced today record financial results and a positive EBITDA for its second quarter and six months ending June 30, 2006.
Total revenues for the three months ended June 30, 2006 were $4,166,182, compared to total revenues of $299,237 for the second quarter of 2005, an increase of over 1,290%. The improved revenues and financial performance on a quarterly comparative basis have primarily resulted from the merger with RiceX and the continued success of the sale of its nutraceutical through direct to consumer marketing during quarter ended December 31, 2005. Approximately 62% of revenues in the quarter were from infomercial sales and 38% from the Company's expanded product lines and increased demand of it value added ingredients for the functional food industry and animal markets.
Total revenues for the six months ended June 30, 2006 were $7,947,726, compared to total revenues of $758,545 for the six months ended June 30, 2005, an increase of over 948%. The significant improvement in improved revenues and financial performance on a quarterly comparative basis are a culmination of the merger with RiceX, direct marketing of its expanding proprietary patented product line and sales of its core products into the functional food industry and animal markets during the quarter ended December 31, 2005.
NutraCea reported net income of $399,434 or $0.01 per share for the second quarter of 2006 based on weighted average shares outstanding of 71,791,913, compared to a net loss of $(1,800,084), or $(0.05) per share in 2005 based on 36,793,254 weighted average shares outstanding.
NutraCea had a net income of $165,860 or $0.00 per share for the six months ended June 30, 2006 based on weighted average shares outstanding of 68,808,345, compared to a net loss of $(2,664,777), or $(0.07) per share in 2005 based on 36,355,262 weighted average shares outstanding.
NutraCea reported positive earnings before interest, taxes, depreciation and amortization (EBITDA)* of $684,559 in the second quarter of 2006 compared to a negative EBITDA of $1,540,175 in the second quarter of 2005, an improvement of $2,224,734. In addition, EBITDA* for the six month period was a positive $717,452 compared to a negative EBITDA of $2,153,530 in the first six months of 2005, an improvement of $2,870,982.
*EBITDA Reconciliation
EBITDA represents net income (loss) before interest, taxes, depreciation and amortization. EBITDA is not a measurement of financial performance under accounting principles generally accepted in the United States. The following table presents EBITDA amounts for the six and three month periods ended June 30, 2006 and 2005. The table also sets forth for these periods a quantitative reconciliation of the differences between EBITDA and net income (loss), as net income (loss) is calculated in accordance with generally accepted accounting principles:
Mr. Brad Edson, President and CEO of NutraCea commented, "We are pleased to report the first profitable quarter in the Company's history and we look forward to executing on our domestic and international business models to achieve sales and profitability in both markets. Since the merger we have reported three consecutive quarters of record revenues, demonstrating our success and leadership as the world's dominant supplier of stabilized rice bran and of value-added ingredients.
Mr. Edson added, "Our expansion plans to increase production capacity of our stabilized rice bran are well underway and expected to be materially accretive to our business during the second half of this year. In this regard, we continue to ramp up revenues and fulfill existing agreements as our additional capacity comes on line, which we believe will allow us to capture more opportunities for sales and implementation of our technology around the world as we move forward. Our capital structure remains strong with no debt on the balance sheet and nearly $15 million in cash."
A conference call is scheduled for today at 11:30 a.m. EDT. Interested parties may participate in the call by dialing 877-407-8037; international callers dial 201-689-8037. In addition, the conference call will be available via a webcast that can be accessed at: http://www.vcall.com/IC/CEPage.asp?ID=107849 and will be archived for 7 days.
About NutraCea
NutraCea is a world leader in stabilized rice bran technology. Through its wholly owned subsidiary RiceX, the Company manufacturers as well as distributes products and food ingredients made from rice bran through its proprietary technology and processes. The Company has developed intellectual property to create a range of proprietary product formulations, delivery systems and whole food nutrition products. NutraCea's proprietary technology enables the creation of food and nutrition products from rice bran, normally a wasted by-product of standard rice processing. In addition to its whole foods products, NutraCea develops families of health promoting "nutraceuticals," including natural arthritic relief and cholesterol-lowering products. More information can be found in the Company's filings with the SEC and you can visit the NutraCea web site http://www.NutraCea.com .
Forward Looking Statements
This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that any increased production capacity will be delayed or reduced in whole or in part, that some or all of the pending matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company's filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission, including the company's most recent periodic report.
Company Contact: Investor Relations Contact:
Margie Adelman Stephen D. Axelrod, CFA
Senior V.P. NutraCea Wolfe Axelrod Weinberger Assoc, LLC
916-933-7000 Ext. 646 212-370-4500
916-220-3500 cell steve@wolfeaxelrod.com
madelman@nutracea.com
Media Relations Contact:
Alisa D. Steinberg
Wolfe Axelrod Weinberger Assoc, LLC
212-370-4500
alisa@wolfeaxelrod.com
INSIDER BUYS!!!!
08/03/2006 ADELMAN, MARGIE 11,765 B Buy
08/03/2006 EDSON, BRADLEY 11,000 B Buy
08/02/2006 NEWLAND, KODY K. 7,000 B Buy
08/02/2006 BENSOL, DAVID S. 5,000 B Buy
08/01/2006 NEWLAND, KODY K. 3,000 B Buy
07/31/2006 EDSON, BRADLEY 10,000 B Buy
Yes all these buys in recent days....Point to fwd growth..
http://www.jmdutton.com/research/ntrz/notes/ntrz_note_081706.pdf
NTRZ...ShakerZZZZZZZZZZ Get in for the GAP..
Dutton confirmed strong Buy..target is 100% up from here....
Heavy Buying goning onnnn
Company Reports Record Net Income of $.01 Per Share
Related newsDow Ends Up Nearly 10 As Rally Fizzles'Talladega' Repeats As Box-Office ChampAftermarket Movers: Agilent JumpsBig Movers in the Stock MarketSector Snap: Copper Notches Gains
EL DORADO HILLS, Calif., Aug. 15 /PRNewswire-FirstCall/ -- NutraCea (OTC Bulletin Board: NTRZ), a world leader in stabilized rice bran research and technology, announced today record financial results and a positive EBITDA for its second quarter and six months ending June 30, 2006.
Total revenues for the three months ended June 30, 2006 were $4,166,182, compared to total revenues of $299,237 for the second quarter of 2005, an increase of over 1,290%. The improved revenues and financial performance on a quarterly comparative basis have primarily resulted from the merger with RiceX and the continued success of the sale of its nutraceutical through direct to consumer marketing during quarter ended December 31, 2005. Approximately 62% of revenues in the quarter were from infomercial sales and 38% from the Company's expanded product lines and increased demand of it value added ingredients for the functional food industry and animal markets.
Total revenues for the six months ended June 30, 2006 were $7,947,726, compared to total revenues of $758,545 for the six months ended June 30, 2005, an increase of over 948%. The significant improvement in improved revenues and financial performance on a quarterly comparative basis are a culmination of the merger with RiceX, direct marketing of its expanding proprietary patented product line and sales of its core products into the functional food industry and animal markets during the quarter ended December 31, 2005.
NutraCea reported net income of $399,434 or $0.01 per share for the second quarter of 2006 based on weighted average shares outstanding of 71,791,913, compared to a net loss of $(1,800,084), or $(0.05) per share in 2005 based on 36,793,254 weighted average shares outstanding.
NutraCea had a net income of $165,860 or $0.00 per share for the six months ended June 30, 2006 based on weighted average shares outstanding of 68,808,345, compared to a net loss of $(2,664,777), or $(0.07) per share in 2005 based on 36,355,262 weighted average shares outstanding.
NutraCea reported positive earnings before interest, taxes, depreciation and amortization (EBITDA)* of $684,559 in the second quarter of 2006 compared to a negative EBITDA of $1,540,175 in the second quarter of 2005, an improvement of $2,224,734. In addition, EBITDA* for the six month period was a positive $717,452 compared to a negative EBITDA of $2,153,530 in the first six months of 2005, an improvement of $2,870,982.
*EBITDA Reconciliation
EBITDA represents net income (loss) before interest, taxes, depreciation and amortization. EBITDA is not a measurement of financial performance under accounting principles generally accepted in the United States. The following table presents EBITDA amounts for the six and three month periods ended June 30, 2006 and 2005. The table also sets forth for these periods a quantitative reconciliation of the differences between EBITDA and net income (loss), as net income (loss) is calculated in accordance with generally accepted accounting principles:
Mr. Brad Edson, President and CEO of NutraCea commented, "We are pleased to report the first profitable quarter in the Company's history and we look forward to executing on our domestic and international business models to achieve sales and profitability in both markets. Since the merger we have reported three consecutive quarters of record revenues, demonstrating our success and leadership as the world's dominant supplier of stabilized rice bran and of value-added ingredients.
Mr. Edson added, "Our expansion plans to increase production capacity of our stabilized rice bran are well underway and expected to be materially accretive to our business during the second half of this year. In this regard, we continue to ramp up revenues and fulfill existing agreements as our additional capacity comes on line, which we believe will allow us to capture more opportunities for sales and implementation of our technology around the world as we move forward. Our capital structure remains strong with no debt on the balance sheet and nearly $15 million in cash."
A conference call is scheduled for today at 11:30 a.m. EDT. Interested parties may participate in the call by dialing 877-407-8037; international callers dial 201-689-8037. In addition, the conference call will be available via a webcast that can be accessed at: http://www.vcall.com/IC/CEPage.asp?ID=107849 and will be archived for 7 days.
About NutraCea
NutraCea is a world leader in stabilized rice bran technology. Through its wholly owned subsidiary RiceX, the Company manufacturers as well as distributes products and food ingredients made from rice bran through its proprietary technology and processes. The Company has developed intellectual property to create a range of proprietary product formulations, delivery systems and whole food nutrition products. NutraCea's proprietary technology enables the creation of food and nutrition products from rice bran, normally a wasted by-product of standard rice processing. In addition to its whole foods products, NutraCea develops families of health promoting "nutraceuticals," including natural arthritic relief and cholesterol-lowering products. More information can be found in the Company's filings with the SEC and you can visit the NutraCea web site http://www.NutraCea.com .
Forward Looking Statements
This release contains forward-looking statements. Actual results may differ from those projected due to a number of risks and uncertainties, including, but not limited to the possibility that any increased production capacity will be delayed or reduced in whole or in part, that some or all of the pending matters and transactions considered by the Company may not proceed as contemplated, and by all other matters specified in the Company's filings with the Securities and Exchange Commission. These statements are made based upon current expectations that are subject to risk and uncertainty. The Company does not undertake to update forward-looking statements in this news release to reflect actual results, changes in assumptions or changes in other factors affecting such forward-looking information. Assumptions and other information that could cause results to differ from those set forth in the forward-looking information can be found in the Company's filings with the Securities and Exchange Commission, including the company's most recent periodic report.
Company Contact: Investor Relations Contact:
Margie Adelman Stephen D. Axelrod, CFA
Senior V.P. NutraCea Wolfe Axelrod Weinberger Assoc, LLC
916-933-7000 Ext. 646 212-370-4500
916-220-3500 cell steve@wolfeaxelrod.com
madelman@nutracea.com
Media Relations Contact:
Alisa D. Steinberg
Wolfe Axelrod Weinberger Assoc, LLC
212-370-4500
alisa@wolfeaxelrod.com
INSIDER BUYS!!!!
08/03/2006 ADELMAN, MARGIE 11,765 B Buy
08/03/2006 EDSON, BRADLEY 11,000 B Buy
08/02/2006 NEWLAND, KODY K. 7,000 B Buy
08/02/2006 BENSOL, DAVID S. 5,000 B Buy
08/01/2006 NEWLAND, KODY K. 3,000 B Buy
07/31/2006 EDSON, BRADLEY 10,000 B Buy
Yes all these buys in recent days....Point to fwd growth..
http://www.jmdutton.com/research/ntrz/notes/ntrz_note_081706.pdf
NTRZ...ShakerZZZZZZZZZZ Get in for the GAP..
Dutton confirmed strong Buy..target is 100% up from here....
Heavy Buying goning onnnn
http://www.taglichbrothers.com/equityuniverse/companies/dermasci/dermasci-07102006.pdf
DSCI About to explode!!.
In short ....Derma Sciences Inc (DSCI) reported Q2 results ended June 2006. Q2 Revenues were $7.39M; +6.64% vs yr-ago; BEATING revenue consensus by +15.83%. Q2 EPS was 1c; 0.00% vs yr-ago; BEATING earnings consensus by +150.00%.
Derma Sciences, Inc., is an integrated manufacturer, marketer and supplier of a complete line of products for wound and skin care. Products fall into five categories: Advanced Wound Care, Traditional Wound Care, Burn Care, Skin Care and Bathing, and Specialty Securement and Closure Devices. With three wholly owned and operated manufacturing facilities in St. Louis, Toronto, and China, the Company offers contract manufacturing services for OEM or private label products.
The Company's wound care products consist of sprays, ointments and dressings for the management of chronic non-healing skin ulcerations, surgical incisions and burns. The Company's specialty fastener products consist of sterile pressure sensitive adhesive wound closure strips, pressure sensitive adhesive catheter fasteners and tubular net dressings. Their general purpose and specialized skincare products consist of body washes, shampoos, an incontinent wash, a moisture barrier ointment, skin moisturizers and lotions, hand washes and sanitizers and a hard surface disinfectant.
The Company's products are used primarily in hospitals, nursing homes, and home health settings. The Company's products include wound dressings, moisturizing lotions, hand soaps, incontinence care products, disinfectants, wound closure strips, and catheter/tubing securement devices. The Company markets its products principally through independent distributors servicing the long-term care, home health and acute care markets in the United States and select international markets.
DSCI released its financials last evening...
Also a little para from the SEC filing Aug 14 2006:
Prospective Assessment
The Company’s objective is to continue to grow sales and gross profit in 2006. Beginning in 2005, the Company expanded its product development efforts. As a result of these efforts, the Company expects to launch two new products in late 2006 and additional new product launches are anticipated in 2007. The April 2006 acquisition of the Western Medical business is anticipated to have a positive impact on the Company’s U.S. business going forward. Growth of the Company’s private label business is anticipated to accelerate in 2006 as the existing business continues to grow and new customers are brought on board. Plans are in place to better leverage existing opportunities in the Company’s basic and advanced wound care lines in the U.S. by working more closely with several key existing and potential new customers to increase business. In Canada, the exclusive distribution agreement represents an opportunity for sales growth in the near future.
The Company plans to build upon its recent success in the area of product cost savings. Higher throughput and improved operational efficiencies are expected to lower the Company’s overall internal cost of manufacturing going forward. Plans are in place to bring the manufacture of the Company’s wound closure-fastener line in-house during 2006 at a savings versus existing third party sourced product costs. The Company also anticipates realizing savings when it begins sterilizing its China sourced products in China in the second half of 2006. Subject to commodity driven cotton prices and foreign exchange changes, which are outside of the Company’s control, the Company anticipates continuing to building on its successful relationships in China to keep its basic wound care costs competitive.
Outstanding Shares: 20 Million Only!!!....on 8/14/2006
Float as of July 2006: 12 Million Only
They gave it a speculative buy with target of 0.95 ....by next JULY....which means at more than 20% rise..
Acquisitions- Last quarter company acquired, for $6.5 million, certain assets (mainly accounts receivable and inventory) and assumed trade payables from Western Medical, Inc., a closely held manufacturer of specialty medical textile compression, support and protective dressings. Western’s products will be combined with Derma Sciences’ wound care line. The company estimates roughly $1 million
The acquisition will add roughly $6.6 million (Western’s 2005 revenue) to Derma Sciences’ annual revenue, contributing an estimated $4.5 million to its 2006 sales. The Western acquisition should support an improvement in profitability; Western’s 2005 gross margin was roughly 39%, well above Derma Sciences’ gross margin for that year. Western’s 2005 pre-tax margin was reported at 11%, also well above Derma Sciences’ for 2005. None of Western’s manufacturing or administrative infrastructure was included in the transaction; those functions are being absorbed by Derma Sciences. With effective integration, most of the gross profit on Western’s revenue could eventually drop down to the operating income line, significantly improving profitability.
CRVU..is ripe and ready..INSIDERS ARE BUYING!!
CRVU.....Revenues Up Up and Above!!
CorVu Reports Strong Fourth Quarter and Full-Year Results
FY2006 Revenues Jump 17% and Net Income Turns Positive
MINNEAPOLIS, July 27 /PRNewswire-FirstCall/ -- CorVu(R) Corporation
(OTC Bulletin Board: CRVU), an innovative provider of Performance
Management software solutions, today announced substantially improved
financial results for the fourth quarter and the twelve month period ended
June 30, 2006.
Fourth-quarter revenues increased 27% to $4.1 million, compared to $3.2
million in the year-ago fourth quarter. For the fourth quarter, the company
reported net income of approximately $680,000 or $0.01 per diluted share,
compared to a net loss of $3.2 million or ($0.10) per diluted share in the
prior year's quarter.
For FY2006, revenues grew 17% to $15.4 million, compared to $13.2
million in FY2005. For FY2006, the company reported net income of
approximately $1.2 million or $0.02 per diluted share, compared to a net
loss of $6.6 million or ($0.20) per diluted share in the same period last
year. Cash and cash equivalents also increased to $3.1 million in FY2006,
compared to $2.2 million at the close of FY2005.
"We are pleased to report substantially improved results for our FY2006
fourth quarter and full year," said Joseph Caffarelli, president and CEO of
CorVu Corporation. "Our revenues grew significantly, and we turned the
corner into profitability as we continued to execute well on our sales
initiatives and maintained our focus on expense control. The 27% growth in
our year-over- year fourth-quarter revenue was driven by a 145% increase in
license revenue. Most importantly, we added 315 new customers during the
year, which bodes well for the future. Finally, during the year we
generated over $940,000 of cash."
During FY2006, CorVu captured a number of significant contracts from a
diverse group of customers, which represent considerable revenue over the
contract lifetimes for software licenses, maintenance, and services. The
company won a major order from a large defense organization with an
estimated value of $800,000; an order from a major international auditing
firm with an estimated value of $700,000; orders from two governmental
agencies with an estimated aggregate value of $800,000; and an order from a
large Middle Eastern mining company with an estimated value of over
$300,000.
Financial Highlights
- Total revenue of $4.1 million for the fourth quarter, a 27% increase
compared to $3.2 million in the year-ago quarter.
- License revenue of $1.7 million for the fourth quarter, a 145% increase
from $0.7 million in the year-ago quarter.
- Total revenue of $15.4 million for the year, a 17% increase compared to
$13.2 million in the prior year.
- License revenue of $6.4 million for the year, a 53% increase from $4.2
million in the prior year.
- Net income totaled $1.2 million for the year, representing 8% return on
revenue and a $7.8 million improvement from last year's net loss of
$6.6 million.
- Cash at June 30, 2006 totaled $3.1 million versus $2.2 million at the
end of last year.
Revenue Summary
Revenues for the fourth quarter totaled $4.1 million, an increase of
27% compared to the year-ago quarter. Software and license fee revenues
totaled $1.7 million for the fourth quarter, an increase of 145% compared
to the year- ago period. Maintenance fees were $1.6 million for the fourth
quarter, a decrease of 8% compared to the year-ago period. Consulting and
other revenues amounted to $0.8 million for the fourth quarter, essentially
unchanged from the year-ago quarter.
Total revenues for the year ended June 30, 2006 were $15.4 million, an
increase of 17% from last year. Software and license fee revenues were $6.4
million for the year ended June 30, 2006, an increase of 53% compared to
the year-ago period. Maintenance fees totaled $6.0 million for the year, an
increase of 3% from last year. Consulting and other revenues were $3.0
million for the year, compared to $3.1 million for the same period last
year.
Expense Summary
Total expenses for the fourth quarter were $3.4 million, down 10% from
$3.8 million in the prior year's quarter. Total expenses for the year ended
June 30, 2006 were $14.1 million, a 17% reduction from $17.0 million for
the same period last year. Expense reductions were driven by restructuring
actions taken at the end of last fiscal year and the first two quarters of
fiscal 2006 which specifically targeted improved operational, logistical
and selling efficiencies. These lower costs, along with redeployed
resources and refocused initiatives, have contributed to improved results.
Balance Sheet
The company's balance sheet at June 30, 2006 showed cash and cash
equivalents of $3.1 million. The company showed positive cash flow for the
year of $0.9 million.
At year-end, net accounts receivable was $3.8 million and deferred
revenues were $5.3 million.
About CorVu Corporation
Pioneering the automation of the balanced scorecard, CorVu has been a
thought leader in performance management software for more than 10 years.
CorVu uniquely combines performance metrics, initiatives, budgeting and
planning, risk management, and reporting in a single application. The CorVu
5 solution is a purpose-built application that is easy to use, scalable,
and rapidly deployable. For more information, visit http://www.corvu.com/.
Supplementary Information:
http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=ind_focus.story&STORY=/www/story/07-27-2006/00...
http://www.taglichbrothers.com/equityuniverse/companies/dermasci/dermasci-07102006.pdf
DSCI About to explode!!..Look at the report by analysts below
Derma Sciences, Inc., is an integrated manufacturer, marketer and supplier of a complete line of products for wound and skin care. Products fall into five categories: Advanced Wound Care, Traditional Wound Care, Burn Care, Skin Care and Bathing, and Specialty Securement and Closure Devices. With three wholly owned and operated manufacturing facilities in St. Louis, Toronto, and China, the Company offers contract manufacturing services for OEM or private label products.
The Company's wound care products consist of sprays, ointments and dressings for the management of chronic non-healing skin ulcerations, surgical incisions and burns. The Company's specialty fastener products consist of sterile pressure sensitive adhesive wound closure strips, pressure sensitive adhesive catheter fasteners and tubular net dressings. Their general purpose and specialized skincare products consist of body washes, shampoos, an incontinent wash, a moisture barrier ointment, skin moisturizers and lotions, hand washes and sanitizers and a hard surface disinfectant.
The Company's products are used primarily in hospitals, nursing homes, and home health settings. The Company's products include wound dressings, moisturizing lotions, hand soaps, incontinence care products, disinfectants, wound closure strips, and catheter/tubing securement devices. The Company markets its products principally through independent distributors servicing the long-term care, home health and acute care markets in the United States and select international markets.
DSCI released its financials last evening...
In short ....Derma Sciences Inc (DSCI) reported Q2 results ended June 2006. Q2 Revenues were $7.39M; +6.64% vs yr-ago; BEATING revenue consensus by +15.83%. Q2 EPS was 1c; 0.00% vs yr-ago; BEATING earnings consensus by +150.00%.
Also a little para from the SEC filing Aug 14 2006:
Prospective Assessment
The Company’s objective is to continue to grow sales and gross profit in 2006. Beginning in 2005, the Company expanded its product development efforts. As a result of these efforts, the Company expects to launch two new products in late 2006 and additional new product launches are anticipated in 2007. The April 2006 acquisition of the Western Medical business is anticipated to have a positive impact on the Company’s U.S. business going forward. Growth of the Company’s private label business is anticipated to accelerate in 2006 as the existing business continues to grow and new customers are brought on board. Plans are in place to better leverage existing opportunities in the Company’s basic and advanced wound care lines in the U.S. by working more closely with several key existing and potential new customers to increase business. In Canada, the exclusive distribution agreement represents an opportunity for sales growth in the near future.
The Company plans to build upon its recent success in the area of product cost savings. Higher throughput and improved operational efficiencies are expected to lower the Company’s overall internal cost of manufacturing going forward. Plans are in place to bring the manufacture of the Company’s wound closure-fastener line in-house during 2006 at a savings versus existing third party sourced product costs. The Company also anticipates realizing savings when it begins sterilizing its China sourced products in China in the second half of 2006. Subject to commodity driven cotton prices and foreign exchange changes, which are outside of the Company’s control, the Company anticipates continuing to building on its successful relationships in China to keep its basic wound care costs competitive.
Outstanding Shares: 20 Million Only!!!....on 8/14/2006
Float as of July 2006: 12 Million Only
Valuation REPORT by TAGLICHBROTHERS
They gave it a speculative buy with target of 0.95 ....by next JULY....which means at more than 20% rise..
Acquisitions- Last quarter company acquired, for $6.5 million, certain assets (mainly accounts receivable and inventory) and assumed trade payables from Western Medical, Inc., a closely held manufacturer of specialty medical textile compression, support and protective dressings. Western’s products will be combined with Derma Sciences’ wound care line. The company estimates roughly $1 million
The acquisition will add roughly $6.6 million (Western’s 2005 revenue) to Derma Sciences’ annual revenue, contributing an estimated $4.5 million to its 2006 sales. The Western acquisition should support an improvement in profitability; Western’s 2005 gross margin was roughly 39%, well above Derma Sciences’ gross margin for that year. Western’s 2005 pre-tax margin was reported at 11%, also well above Derma Sciences’ for 2005. None of Western’s manufacturing or administrative infrastructure was included in the transaction; those functions are being absorbed by Derma Sciences. With effective integration, most of the gross profit on Western’s revenue could eventually drop down to the operating income line, significantly improving profitability.
This is not a recommendation to buy or sell securities. This message represents my personal opinion. Visit http://stockdoctor.blogspot.com for more of my picks.
http://www.taglichbrothers.com/equityuniverse/companies/dermasci/dermasci-07102006.pdf
DSCI About to explode!!..Look at the report by analysts below
Derma Sciences, Inc., is an integrated manufacturer, marketer and supplier of a complete line of products for wound and skin care. Products fall into five categories: Advanced Wound Care, Traditional Wound Care, Burn Care, Skin Care and Bathing, and Specialty Securement and Closure Devices. With three wholly owned and operated manufacturing facilities in St. Louis, Toronto, and China, the Company offers contract manufacturing services for OEM or private label products.
The Company's wound care products consist of sprays, ointments and dressings for the management of chronic non-healing skin ulcerations, surgical incisions and burns. The Company's specialty fastener products consist of sterile pressure sensitive adhesive wound closure strips, pressure sensitive adhesive catheter fasteners and tubular net dressings. Their general purpose and specialized skincare products consist of body washes, shampoos, an incontinent wash, a moisture barrier ointment, skin moisturizers and lotions, hand washes and sanitizers and a hard surface disinfectant.
The Company's products are used primarily in hospitals, nursing homes, and home health settings. The Company's products include wound dressings, moisturizing lotions, hand soaps, incontinence care products, disinfectants, wound closure strips, and catheter/tubing securement devices. The Company markets its products principally through independent distributors servicing the long-term care, home health and acute care markets in the United States and select international markets.
DSCI released its financials last evening...
In short ....Derma Sciences Inc (DSCI) reported Q2 results ended June 2006. Q2 Revenues were $7.39M; +6.64% vs yr-ago; BEATING revenue consensus by +15.83%. Q2 EPS was 1c; 0.00% vs yr-ago; BEATING earnings consensus by +150.00%.
Also a little para from the SEC filing Aug 14 2006:
Prospective Assessment
The Company’s objective is to continue to grow sales and gross profit in 2006. Beginning in 2005, the Company expanded its product development efforts. As a result of these efforts, the Company expects to launch two new products in late 2006 and additional new product launches are anticipated in 2007. The April 2006 acquisition of the Western Medical business is anticipated to have a positive impact on the Company’s U.S. business going forward. Growth of the Company’s private label business is anticipated to accelerate in 2006 as the existing business continues to grow and new customers are brought on board. Plans are in place to better leverage existing opportunities in the Company’s basic and advanced wound care lines in the U.S. by working more closely with several key existing and potential new customers to increase business. In Canada, the exclusive distribution agreement represents an opportunity for sales growth in the near future.
The Company plans to build upon its recent success in the area of product cost savings. Higher throughput and improved operational efficiencies are expected to lower the Company’s overall internal cost of manufacturing going forward. Plans are in place to bring the manufacture of the Company’s wound closure-fastener line in-house during 2006 at a savings versus existing third party sourced product costs. The Company also anticipates realizing savings when it begins sterilizing its China sourced products in China in the second half of 2006. Subject to commodity driven cotton prices and foreign exchange changes, which are outside of the Company’s control, the Company anticipates continuing to building on its successful relationships in China to keep its basic wound care costs competitive.
Outstanding Shares: 20 Million Only!!!....on 8/14/2006
Float as of July 2006: 12 Million Only
Valuation REPORT by TAGLICHBROTHERS
They gave it a speculative buy with target of 0.95 ....by next JULY....which means at more than 20% rise..
Acquisitions- Last quarter company acquired, for $6.5 million, certain assets (mainly accounts receivable and inventory) and assumed trade payables from Western Medical, Inc., a closely held manufacturer of specialty medical textile compression, support and protective dressings. Western’s products will be combined with Derma Sciences’ wound care line. The company estimates roughly $1 million
The acquisition will add roughly $6.6 million (Western’s 2005 revenue) to Derma Sciences’ annual revenue, contributing an estimated $4.5 million to its 2006 sales. The Western acquisition should support an improvement in profitability; Western’s 2005 gross margin was roughly 39%, well above Derma Sciences’ gross margin for that year. Western’s 2005 pre-tax margin was reported at 11%, also well above Derma Sciences’ for 2005. None of Western’s manufacturing or administrative infrastructure was included in the transaction; those functions are being absorbed by Derma Sciences. With effective integration, most of the gross profit on Western’s revenue could eventually drop down to the operating income line, significantly improving profitability.
This is not a recommendation to buy or sell securities. This message represents my personal opinion. Visit http://stockdoctor.blogspot.com for more of my picks.
http://www.taglichbrothers.com/equityuniverse/companies/dermasci/dermasci-07102006.pdf
DSCI About to explode!!..Look at the report by analysts below
Derma Sciences, Inc., is an integrated manufacturer, marketer and supplier of a complete line of products for wound and skin care. Products fall into five categories: Advanced Wound Care, Traditional Wound Care, Burn Care, Skin Care and Bathing, and Specialty Securement and Closure Devices. With three wholly owned and operated manufacturing facilities in St. Louis, Toronto, and China, the Company offers contract manufacturing services for OEM or private label products.
The Company's wound care products consist of sprays, ointments and dressings for the management of chronic non-healing skin ulcerations, surgical incisions and burns. The Company's specialty fastener products consist of sterile pressure sensitive adhesive wound closure strips, pressure sensitive adhesive catheter fasteners and tubular net dressings. Their general purpose and specialized skincare products consist of body washes, shampoos, an incontinent wash, a moisture barrier ointment, skin moisturizers and lotions, hand washes and sanitizers and a hard surface disinfectant.
The Company's products are used primarily in hospitals, nursing homes, and home health settings. The Company's products include wound dressings, moisturizing lotions, hand soaps, incontinence care products, disinfectants, wound closure strips, and catheter/tubing securement devices. The Company markets its products principally through independent distributors servicing the long-term care, home health and acute care markets in the United States and select international markets.
DSCI released its financials last evening...
In short ....Derma Sciences Inc (DSCI) reported Q2 results ended June 2006. Q2 Revenues were $7.39M; +6.64% vs yr-ago; BEATING revenue consensus by +15.83%. Q2 EPS was 1c; 0.00% vs yr-ago; BEATING earnings consensus by +150.00%.
Also a little para from the SEC filing Aug 14 2006:
Prospective Assessment
The Company’s objective is to continue to grow sales and gross profit in 2006. Beginning in 2005, the Company expanded its product development efforts. As a result of these efforts, the Company expects to launch two new products in late 2006 and additional new product launches are anticipated in 2007. The April 2006 acquisition of the Western Medical business is anticipated to have a positive impact on the Company’s U.S. business going forward. Growth of the Company’s private label business is anticipated to accelerate in 2006 as the existing business continues to grow and new customers are brought on board. Plans are in place to better leverage existing opportunities in the Company’s basic and advanced wound care lines in the U.S. by working more closely with several key existing and potential new customers to increase business. In Canada, the exclusive distribution agreement represents an opportunity for sales growth in the near future.
The Company plans to build upon its recent success in the area of product cost savings. Higher throughput and improved operational efficiencies are expected to lower the Company’s overall internal cost of manufacturing going forward. Plans are in place to bring the manufacture of the Company’s wound closure-fastener line in-house during 2006 at a savings versus existing third party sourced product costs. The Company also anticipates realizing savings when it begins sterilizing its China sourced products in China in the second half of 2006. Subject to commodity driven cotton prices and foreign exchange changes, which are outside of the Company’s control, the Company anticipates continuing to building on its successful relationships in China to keep its basic wound care costs competitive.
Outstanding Shares: 20 Million Only!!!....on 8/14/2006
Float as of July 2006: 12 Million Only
Valuation REPORT by TAGLICHBROTHERS
They gave it a speculative buy with target of 0.95 ....by next JULY....which means at more than 20% rise..
Acquisitions- Last quarter company acquired, for $6.5 million, certain assets (mainly accounts receivable and inventory) and assumed trade payables from Western Medical, Inc., a closely held manufacturer of specialty medical textile compression, support and protective dressings. Western’s products will be combined with Derma Sciences’ wound care line. The company estimates roughly $1 million
The acquisition will add roughly $6.6 million (Western’s 2005 revenue) to Derma Sciences’ annual revenue, contributing an estimated $4.5 million to its 2006 sales. The Western acquisition should support an improvement in profitability; Western’s 2005 gross margin was roughly 39%, well above Derma Sciences’ gross margin for that year. Western’s 2005 pre-tax margin was reported at 11%, also well above Derma Sciences’ for 2005. None of Western’s manufacturing or administrative infrastructure was included in the transaction; those functions are being absorbed by Derma Sciences. With effective integration, most of the gross profit on Western’s revenue could eventually drop down to the operating income line, significantly improving profitability.
This is not a recommendation to buy or sell securities. This message represents my personal opinion. Visit http://stockdoctor.blogspot.com for more of my picks.
My Target: get in before the crowd!!! Get out before the crowd!!!
DSCI About to explode!!..Look at the report by analysts below
Derma Sciences, Inc., is an integrated manufacturer, marketer and supplier of a complete line of products for wound and skin care. Products fall into five categories: Advanced Wound Care, Traditional Wound Care, Burn Care, Skin Care and Bathing, and Specialty Securement and Closure Devices. With three wholly owned and operated manufacturing facilities in St. Louis, Toronto, and China, the Company offers contract manufacturing services for OEM or private label products.
The Company's wound care products consist of sprays, ointments and dressings for the management of chronic non-healing skin ulcerations, surgical incisions and burns. The Company's specialty fastener products consist of sterile pressure sensitive adhesive wound closure strips, pressure sensitive adhesive catheter fasteners and tubular net dressings. Their general purpose and specialized skincare products consist of body washes, shampoos, an incontinent wash, a moisture barrier ointment, skin moisturizers and lotions, hand washes and sanitizers and a hard surface disinfectant.
The Company's products are used primarily in hospitals, nursing homes, and home health settings. The Company's products include wound dressings, moisturizing lotions, hand soaps, incontinence care products, disinfectants, wound closure strips, and catheter/tubing securement devices. The Company markets its products principally through independent distributors servicing the long-term care, home health and acute care markets in the United States and select international markets.
DSCI released its financials last evening...
In short ....Derma Sciences Inc (DSCI) reported Q2 results ended June 2006. Q2 Revenues were $7.39M; +6.64% vs yr-ago; BEATING revenue consensus by +15.83%. Q2 EPS was 1c; 0.00% vs yr-ago; BEATING earnings consensus by +150.00%.
Also a little para from the SEC filing Aug 14 2006:
Prospective Assessment
The Company’s objective is to continue to grow sales and gross profit in 2006. Beginning in 2005, the Company expanded its product development efforts. As a result of these efforts, the Company expects to launch two new products in late 2006 and additional new product launches are anticipated in 2007. The April 2006 acquisition of the Western Medical business is anticipated to have a positive impact on the Company’s U.S. business going forward. Growth of the Company’s private label business is anticipated to accelerate in 2006 as the existing business continues to grow and new customers are brought on board. Plans are in place to better leverage existing opportunities in the Company’s basic and advanced wound care lines in the U.S. by working more closely with several key existing and potential new customers to increase business. In Canada, the exclusive distribution agreement represents an opportunity for sales growth in the near future.
The Company plans to build upon its recent success in the area of product cost savings. Higher throughput and improved operational efficiencies are expected to lower the Company’s overall internal cost of manufacturing going forward. Plans are in place to bring the manufacture of the Company’s wound closure-fastener line in-house during 2006 at a savings versus existing third party sourced product costs. The Company also anticipates realizing savings when it begins sterilizing its China sourced products in China in the second half of 2006. Subject to commodity driven cotton prices and foreign exchange changes, which are outside of the Company’s control, the Company anticipates continuing to building on its successful relationships in China to keep its basic wound care costs competitive.
Outstanding Shares: 20 Million Only!!!....on 8/14/2006
Float as of July 2006: 12 Million Only
Valuation REPORT by TAGLICHBROTHERS
http://www.taglichbrothers.com/equityuniverse/companies/dermasci/dermasci-07102006.pdf
They gave it a speculative buy with target of 0.95 ....by next JULY....which means at more than 20% rise..
Acquisitions- Last quarter company acquired, for $6.5 million, certain assets (mainly accounts receivable and inventory) and assumed trade payables from Western Medical, Inc., a closely held manufacturer of specialty medical textile compression, support and protective dressings. Western’s products will be combined with Derma Sciences’ wound care line. The company estimates roughly $1 million
The acquisition will add roughly $6.6 million (Western’s 2005 revenue) to Derma Sciences’ annual revenue, contributing an estimated $4.5 million to its 2006 sales. The Western acquisition should support an improvement in profitability; Western’s 2005 gross margin was roughly 39%, well above Derma Sciences’ gross margin for that year. Western’s 2005 pre-tax margin was reported at 11%, also well above Derma Sciences’ for 2005. None of Western’s manufacturing or administrative infrastructure was included in the transaction; those functions are being absorbed by Derma Sciences. With effective integration, most of the gross profit on Western’s revenue could eventually drop down to the operating income line, significantly improving profitability.
CYRO Collect for the ride next week...
news out
Chyron Appoints Broadcast Graphics Veteran Aldo Campisi as Product Manager
Friday , August 18, 2006 10:25 ET
MELVILLE, N.Y., Aug 18, 2006 (BUSINESS WIRE) -- Chyron Corporation (OTC BB: CYRO) has today announced the appointment of broadcast graphics veteran Aldo Campisi as Product Manager. Campisi will be an integral part of the team responsible for new product introductions, market branding and product awareness and will be based at Chyron's Melville, NY headquarters.
Campisi brings a diverse and comprehensive understanding of the broadcast graphics marketplace to Chyron. He has an established industry background, which started at Canada's Weather Network (TWN), in Toronto where he worked as a Graphic Specialist. Campisi also served as Commercial Production Manager, responsible for the creation and development of all aspects of TWN's graphics programming and commercial requirements, as well as Operations Manager, in which he oversaw the channel's creative, technical and operational requirements for the daily execution of all graphic elements interfaced to raw weather data.
Following his success at TWN, Campisi continued to work internationally to support graphics design for the Turner Sports Network during the 2001 Goodwill Games in Brisbane, Australia and then pursued onwards to the 2002 World Cup Soccer tournament coverage to provide graphics support for TELEVISA. In 2004, he went on to craft, implement and support broadcast graphics for NBC's 2004 Olympic Games in Athens, Greece. He has also worked with other major networks including the Canadian Broadcasting Corporation, CTV Network, BBC, TV Azteca, Univision, Fox News and Sports, CNN, RAI, A&E Mundo and Sony Entertainment Television.
Commenting on his new role at Chyron Campisi commented, "Chyron provides a benchmark for broadcast quality graphics and I am delighted to become a part of its highly professional team. The company's portfolio is extremely sound and well respected in the industry and I am looking forward to further extending its potential."
According to Chyron CEO Michael Wellesley-Wesley, "Aldo was a perfect choice for the position. His highly successful track record is a result of his expertise and technical knowledge of broadcast graphics. Aldo will be influential in taking Chyron to the next level as we continue introducing new products and expanding our market."
About Chyron
With unwavering clarity of vision, Chyron continues to define and dominate the world of broadcast graphics. Winner of numerous awards, including two Emmys, Chyron has proven itself as the undisputed leader in the industry. From the compact MicroX to the HD/SD HyperX with Lyric PRO, Chyron's exceptional product line brings unmatched, 2D and 3D graphics creation and performance to the most demanding studio and mobile operations. Rounding out Chyron's graphics offerings are still and clip servers, channel branding and telestration systems, and MOS newsroom integration solutions. The ChyTV product line leverages Chyron's broadcast expertise with video graphics devices for microcasting and digital displays. Chyron holds a patent on technology that enables the integration of live television graphics data with a broad range of interactive media platforms and consumer electronics devices. Chyron has a unique, 40-year history of service and support for its products that far exceeds that of most manufacturers. For more information about Chyron products and services, please visit the company web sites at www.chyron.com and www.chytv.com (OTC BB:CYRO.OB).
Product Images available on request
SOURCE: Chyron Corporation
Chyron Corporation
Michelle Ingram, 631-845-2051
michelle@chyron.com
or
Press:
Manor Marketing
Jennie Evans, + 44 1635 44991
jennie@manormarketing.tv
Copyright Business Wire 2006
NTRZ..Gap in am...MOMO..Look inside
Take a look at this report BY DUTTON.....STRONG BUY
http://www.jmdutton.com/research/ntrz/notes/ntrz_note_081706.pdf
NTRZ...ShakerZZZZZZZZZZ Get in for the GAP in am..
Dutton confirmed strong Buy..target is 100% up from here....
Heavy Buying goning onnnn
http://www.jmdutton.com/research/ntrz/notes/ntrz_note_081706.pdf
CXIA..30% up..on Earnings news coming SUNDAY...
3 contracts on hand.
New Govt. contract recently signed.
Jump up next weeek....
I would through $500 at this puppyyyy
Go baby goooo
Also very low float...JUMPS on little volume
FRXX..IBM contract ..10% UP ..POP in making!!!
Earnings coming out soon....
Forecross Signs $1,928,500.00 Migration Contract
SAN FRANCISCO--(BUSINESS WIRE)--Aug. 10, 2006--Forecross(R) Corporation, a legacy-to-web and XML implementation solutions company announced today that it has signed a new contract with a premier information technology services company for the conversion of certain CA-IDMS applications to IBM's DB2. Forecross will perform the migration as a sub-contractor for the benefit of an agency of state government. As part of this contract, Forecross will also provide maintenance and enhancements to certain other applications.
"This is our third major migration project with this particular customer," commented Bernadette C. Castello, Senior Vice President and CFO, Forecross Corporation. "It acknowledges their confidence in our company and our superior technology."
In a separate development, Forecross also signed a contract valued at $25,000, for the migration of a small system written in IBM's Cross System Product for a midwestern energy company.
Founded in 1982 as a high-technology software development laboratory, Forecross Corporation is dedicated to the design and development of innovative conversion software to re-deploy and sustain legacy applications on the Internet. Clients have included such leading corporations as Aetna Life Insurance Company, Brown Brothers Harriman & Company, Charles Schwab & Co., the University of California at San Diego, BDM Technologies, Inc., IBM Corporation and Bank of America NTSA for its migration software services. Teaming partners of Forecross Corporation include U.S. Technology Resources, Inc., CIBER, Inc. and SCB Computer Technology, Inc.
On Behalf of the Board of Directors,
Bernadette C. Castello
Senior VP, CFO
FORECROSS CORPORATION
Except for historical information contained herein, the matters set forth in this release are forward-looking statements that are dependent on certain risks and uncertainties, including such factors, among others, as market acceptance, market demand, pricing, changing regulatory environment, changing economic conditions, risks in new product and service development, the effect of the company's accounting policies and other risk factors detailed in the Company's SEC and BCSC filings.
The U.S. Securities and Exchange Commission has not reviewed and does not accept responsibility for the adequacy or accuracy of this News Release, which has been prepared by the Company.
Forecross is a registered trademark of Forecross Corporation.
CXIA.....10% UP...Earnings coming SUNDAY...
Should run tomorrow and next week after the earnings
Do ur DD...Call company investor relation GUY
Company has been getting contracts since 2004....Has to run up next week after +++++ earnings report..
Lots of interest developing
NTRZ ...Target of 1.80 according to DUTTON
Get in for the ride....
All day there have been BUYS.....
NTRZ.....Look at it TTOON....(+1290% earnings) I have been telling everybody
This is not a regular company.....
This is the time to get in before it JUMPS soooo very away
Look at all the earnings..They made 1290% more than last YEAR!!!
CXIA....SharkerZZZZZZZZZ....Earnings coming SUNDAY
Get in before the VIOLENT JUMP
Hoooooo
Lets Gooooooooo!!!
I am all pumped up ....
They recently got several contracts...Do ur DD
FRXX...Up on speculation of earnings coming out soon...
Lets gooooo!!!!!!
FRXX 9% up on speculation of earnings....
Should pass 0.05 sooon
Lets go..
FRXX....ON Fire 19% up....
Earnings coming out soon.....
Get in for a x10 bagger
FRXX...Look at it flyyyyyyyy
Go Go Go baby!!
Earnings coming out and it will fly..
CRVU ..Insiders Buying
08/10/2006 CAFFARELLI, JOSEPH 400 B Buy
08/09/2006 CAFFARELLI, JOSEPH 400 B Buy
08/08/2006 CAFFARELLI, JOSEPH 400 B Buy
08/07/2006 CAFFARELLI, JOSEPH 300 B Buy
Earnings ++++
CXIA reporting earnings on SUNDAY...
CXIA: Awarded Remediation Demonstration Contract From the Department of Energy's Office of Environmental Management
Monday , August 14, 2006 11:42 ET
Commodore Applied Technologies, Inc. (CXIA) announced that the Company's wholly owned subsidiary, Commodore Advanced Sciences, Inc., has been awarded an Advanced Remediation Demonstration contract by the Department of Energy's Office of Environmental Management (DOE-EM) for the Company's technology for the separation of radioactive (surrogate) and RCRA heavy metals from sludges and other waste matrices.
The DOE-EM awarded 12 contracts totaling $3.3 million to support the development of technologies that have the potential to reduce cleanup costs and increase the safety and efficiency of treating and disposing of various waste streams, including radioactive waste at such sites as Hanford, Idaho, Savannah River, and others.
CASI's Phase I contract will be performed over a six month period. Phase I proposed activities include: laboratory/pilot-scale test results, developing a technical approach for demonstration, scale-up and implementation schedule, detailed system design, and a detailed cost estimate for implementation in Phase II.
NTRZ...last 10 min BUYS alert...
Get ready for a BOOOOOOOM here...
Good Luck..This should go for several weeks uptrend from here
Lots of Buys going in...last few mintutes
Seems like it would be BIG over next week
NTRZ GAP in am.. did someone see what happened at the EOD..
TONS Of Buys...
HUGE stacks of shares traded!!
LOOK OUT
FRXX...X10 Bagger....
This thing is loading up for FIRE!!
NTRZ...Lets gooo +1290% earnings reported..
Profit taking is over now it goes to the MOOOON!!
NutraCea Announces Record 2nd Quarter Results and Gilead Licenses HIV Drug to 3 Companies
City of Industry, CA --(www.FinancialNewsUSA.com)-- 08/16/2006 - Biotechnology industry news provided by Financial News USA. NutraCea (OTC BB: NTRZ), a world leader in stabilized rice bran research and technology, recently announced record financial results and a positive EBITDA for its second quarter and six months ending June 30, 2006. Total revenues for the three months ended June 30, 2006 were $4,166,182, compared to total revenues of $299,237 for the second quarter of 2005, an increase of over 1,290%. MedImmune, Inc. (Nasdaq: MEDI) announced recently that it has promoted Edward T. Mathers to executive vice president, corporate development and venture. In this role, he is responsible for the company's licensing and business development activities and is a key leader of the company's MedImmune Ventures, Inc. team evaluating investment opportunities. MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders.
Biopharmaceutical Company Gilead Sciences Inc. (Nasdaq:GILD) said Monday it signed three non-exclusive licensing agreements for generic versions its HIV drug Viread with Indian manufacturers. The agreements grant Emcure Pharmaceuticals Ltd., Hetero Drugs Ltd. and Strides Arcolab Ltd. rights to make and distribute tenofovir disoproxil fumarate to 95 low-income countries around the world, including India. CV Therapeutics Inc.(NASDAQ:CVTX) stock hit a 52-week low on Monday after it said it will offer 7.5 million shares for sale. CV, which had about 14.3 million shares of common stock outstanding before the new offering, closed at $9.76 Monday. It has lost about two-thirds of its value since Sept. 12 when it traded at $29.79. Palo Alto-based CV has racked up more than $800 million in net losses in the past five and one-half years.
About Financial News USA
Financial News USA is a Next Generation Financial Communications firm focused on the distribution of market moving news. Financial News USA has developed leading edge e-publishing tools including programming proprietary RSS feeds and enabling open source press release publishing across its network. Financial News USA has been aggressively expanding its news distribution network by targeting direct feeds to financial news and data providers such as FinancialContent, Yahoo (NASDAQ: YHOO), among others. Financial News USA offers a free news feed available online (www.financialnewsusa.com) to websites and financial services looking for content and for individual investors looking to stay informed on the financial markets. Financial News USA and its affiliates charge each client cash for news distribution and may take an equity position in the companies mentioned herein, please visit the disclaimer at www.financialnewsusa.com
Contact Information:
Financial News USA
Tel: (626) 961-8041
Email: info@financialnewsusa.com
CXIA..Earnings to be out SUNDAy...Should JUMP up considering 3 contracts coming out...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported: August 14, 2006)
COMMODORE APPLIED TECHNOLOGIES, INC.
-------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 1-11871 11-3312952
---------------------- --------------------- -------------------------
(State or other (Commission (I.R.S. Employer
jurisdiction File Number) Identification No.)
of incorporation)
150 East 58th Street, Suite 3238 10155
New York, New York
-------------------------------------------- -------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (212) 308-5800
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
CURRENT REPORT ON FORM 8-K
COMMODORE APPLIED TECHNOLOGIES, INC.
August 16, 2006
ITEM 7.01 REGULATION FD DISCLOSURE
On August 14, 2006, Commodore Applied Technologies, Inc. (the
"Company") issued a press release announcing that it wholly owned subsidiary,
Commodore Advanced Sciences, Inc., has been awarded an Advanced Remediation
Demonstration Phase 1 contract by the Department of Energy's Environmental
Management Office for the separation of radioactive (surrogate) and RCRA heavy
metals from sludges and other waste matrices.
A copy of the press release is furnished as Exhibit 99.1.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
99.1 Press Release dated August 14, 2006.
2
<PAGE>
The information contained in this report is being furnished pursuant to
Item 7.01, Regulation FD Disclosure, and Item 9.01, Financial Statements and
Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Current Report to be signed on its behalf by
the undersigned thereunto duly authorized.
COMMODORE APPLIED TECHNOLOGIES, INC.
Date: August 16, 2006 By: /s/ James M. DeAngelis
-------------------------
James M. DeAngelis
Senior Vice President and
Chief Financial Officer
3
<PAGE>
EXHIBIT INDEX
Exhibit No.
-----------
99.1 Press Release dated August 14, 2006 issued by Commodore
Applied Technologies, Inc.
4
</TEXT>
</DOCUMENT>
Exhibit 99.1
------------
AB
NEWS RELEASE
For release: Immediate
Contact: James M. DeAngelis - (212) 308-5800
Commodore Applied Technologies, Inc.
o Commodore Advanced Sciences wins Advanced Remediation
Demonstration Contract from the Department of Energy's Office of
Environmental Management
NEW YORK, NY - August 14, 2006 - Commodore Applied Technologies, Inc. (OTCBB:
CXIA), today announced that the Company's wholly owned subsidiary, Commodore
Advanced Sciences, Inc., (CASI) has been awarded an Advanced Remediation
Demonstration contract by the Department of Energy's Office of Environmental
Management (DOE-EM) for the Company's technology for the separation of
radioactive (surrogate) and RCRA heavy metals from sludges and other waste
matrices.
The DOE-EM awarded 12 contracts totaling $3.3 million to support the development
of technologies that have the potential to reduce cleanup costs and increase the
safety and efficiency of treating and disposing of various waste streams,
including radioactive waste at such sites as Hanford, Idaho, Savannah River, and
others.
- more -
<PAGE>
CASI DOE Contract
August 14, 2006
Page 2
CASI's Phase I contract will be performed over a six month period. Phase I
proposed activities include: laboratory/pilot-scale test results, developing a
technical approach for demonstration, scale-up and implementation schedule,
detailed system design, and a detailed cost estimate for implementation in Phase
II.
Chairman and CEO Mr. Shelby Brewer said: "Over the past several years, CASI has
focused on the delivery of innovative environmental services to the DOE-EM. This
recent contract award will allow us to expand our technology offerings to the
DOE-EM to assist them in their ongoing efforts to provide the safest, most cost
effective waste treatment processes for their facilities."
Commodore Applied Technologies, Inc. is a diverse technical solutions company
focused on high-end environmental markets. The Commodore family of companies
includes subsidiaries Commodore Solution Technologies and Commodore Advanced
Sciences. The Commodore companies provide technical services and patented
remediation technologies designed to treat hazardous waste from nuclear and
chemical sources. More information is available on the Commodore web site at
www.commodore.com.
- more -
<PAGE>
CASI DOE Contract
August 14, 2006
Page 3
This Press Release contains forward-looking statements that are based on our
current expectations, beliefs and assumptions about the industry and markets in
which Commodore Applied Technologies, Inc. and its subsidiaries operate. Such
forward-looking statements involve known and unknown risks, uncertainties, and
other factors that may cause Commodore's actual results to be materially
different from any future results expressed or implied by these statements.
Actual results may differ materially from what is expressed in these statements,
and no assurance can be given that Commodore can successfully implement its core
business strategy and improve future earnings.
The factors that may cause Commodore's actual results to differ from its
forward-looking statements include: Commodore's current critical need for
additional cash to sustain existing operations and meet ongoing existing
obligations and capital requirements; Commodore's ability to implement its
commercial waste processing operations, including obtaining commercial waste
processing contracts and processing waste under such contracts in a timely and
cost-effective manner; the timing and award of contracts by the U.S. Department
of Energy for the clean-up of waste sites administered by it; the acceptance and
implementation of Commodore's waste treatment technologies in the government and
commercial sectors; and other large technical support services projects. All
forward-looking statements are also expressly qualified in their entirety by the
cautionary statements included in Commodore's SEC filings, including its
quarterly reports on Form 10-Q and its annual report on Form 10-K.
###
FRXX...Holding bid and ask up....Should POP with earnings report
CXIA..Earnings to be out SUNDAy...Should JUMP up considering 3 contracts coming out...
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
-----------------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported: August 14, 2006)
COMMODORE APPLIED TECHNOLOGIES, INC.
-------------------------------------------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 1-11871 11-3312952
---------------------- --------------------- -------------------------
(State or other (Commission (I.R.S. Employer
jurisdiction File Number) Identification No.)
of incorporation)
150 East 58th Street, Suite 3238 10155
New York, New York
-------------------------------------------- -------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (212) 308-5800
--------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
<PAGE>
CURRENT REPORT ON FORM 8-K
COMMODORE APPLIED TECHNOLOGIES, INC.
August 16, 2006
ITEM 7.01 REGULATION FD DISCLOSURE
On August 14, 2006, Commodore Applied Technologies, Inc. (the
"Company") issued a press release announcing that it wholly owned subsidiary,
Commodore Advanced Sciences, Inc., has been awarded an Advanced Remediation
Demonstration Phase 1 contract by the Department of Energy's Environmental
Management Office for the separation of radioactive (surrogate) and RCRA heavy
metals from sludges and other waste matrices.
A copy of the press release is furnished as Exhibit 99.1.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
99.1 Press Release dated August 14, 2006.
2
<PAGE>
The information contained in this report is being furnished pursuant to
Item 7.01, Regulation FD Disclosure, and Item 9.01, Financial Statements and
Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Current Report to be signed on its behalf by
the undersigned thereunto duly authorized.
COMMODORE APPLIED TECHNOLOGIES, INC.
Date: August 16, 2006 By: /s/ James M. DeAngelis
-------------------------
James M. DeAngelis
Senior Vice President and
Chief Financial Officer
3
<PAGE>
EXHIBIT INDEX
Exhibit No.
-----------
99.1 Press Release dated August 14, 2006 issued by Commodore
Applied Technologies, Inc.
4
</TEXT>
</DOCUMENT>
Exhibit 99.1
------------
AB
NEWS RELEASE
For release: Immediate
Contact: James M. DeAngelis - (212) 308-5800
Commodore Applied Technologies, Inc.
o Commodore Advanced Sciences wins Advanced Remediation
Demonstration Contract from the Department of Energy's Office of
Environmental Management
NEW YORK, NY - August 14, 2006 - Commodore Applied Technologies, Inc. (OTCBB:
CXIA), today announced that the Company's wholly owned subsidiary, Commodore
Advanced Sciences, Inc., (CASI) has been awarded an Advanced Remediation
Demonstration contract by the Department of Energy's Office of Environmental
Management (DOE-EM) for the Company's technology for the separation of
radioactive (surrogate) and RCRA heavy metals from sludges and other waste
matrices.
The DOE-EM awarded 12 contracts totaling $3.3 million to support the development
of technologies that have the potential to reduce cleanup costs and increase the
safety and efficiency of treating and disposing of various waste streams,
including radioactive waste at such sites as Hanford, Idaho, Savannah River, and
others.
- more -
<PAGE>
CASI DOE Contract
August 14, 2006
Page 2
CASI's Phase I contract will be performed over a six month period. Phase I
proposed activities include: laboratory/pilot-scale test results, developing a
technical approach for demonstration, scale-up and implementation schedule,
detailed system design, and a detailed cost estimate for implementation in Phase
II.
Chairman and CEO Mr. Shelby Brewer said: "Over the past several years, CASI has
focused on the delivery of innovative environmental services to the DOE-EM. This
recent contract award will allow us to expand our technology offerings to the
DOE-EM to assist them in their ongoing efforts to provide the safest, most cost
effective waste treatment processes for their facilities."
Commodore Applied Technologies, Inc. is a diverse technical solutions company
focused on high-end environmental markets. The Commodore family of companies
includes subsidiaries Commodore Solution Technologies and Commodore Advanced
Sciences. The Commodore companies provide technical services and patented
remediation technologies designed to treat hazardous waste from nuclear and
chemical sources. More information is available on the Commodore web site at
www.commodore.com.
- more -
<PAGE>
CASI DOE Contract
August 14, 2006
Page 3
This Press Release contains forward-looking statements that are based on our
current expectations, beliefs and assumptions about the industry and markets in
which Commodore Applied Technologies, Inc. and its subsidiaries operate. Such
forward-looking statements involve known and unknown risks, uncertainties, and
other factors that may cause Commodore's actual results to be materially
different from any future results expressed or implied by these statements.
Actual results may differ materially from what is expressed in these statements,
and no assurance can be given that Commodore can successfully implement its core
business strategy and improve future earnings.
The factors that may cause Commodore's actual results to differ from its
forward-looking statements include: Commodore's current critical need for
additional cash to sustain existing operations and meet ongoing existing
obligations and capital requirements; Commodore's ability to implement its
commercial waste processing operations, including obtaining commercial waste
processing contracts and processing waste under such contracts in a timely and
cost-effective manner; the timing and award of contracts by the U.S. Department
of Energy for the clean-up of waste sites administered by it; the acceptance and
implementation of Commodore's waste treatment technologies in the government and
commercial sectors; and other large technical support services projects. All
forward-looking statements are also expressly qualified in their entirety by the
cautionary statements included in Commodore's SEC filings, including its
quarterly reports on Form 10-Q and its annual report on Form 10-K.
###
NTRZ..Stockguru alert..Heavy Volume
NutraCea (OTCBB:NTRZ) - Tuesday's shares closed down at -7.37% with a price of $0.880. The volume was at 848,690. NutraCea , a world leader in stabilized rice bran research and technology, announced today record financial results and a positive EBITDA for its second quarter and six months ending June 30, 2006. Total revenues for the three months ended June 30, 2006 were $4,166,182, compared to total revenues of $299,237 for the second quarter of 2005, an increase of over 1,290%. The improved revenues and financial performance on a quarterly comparative basis have primarily resulted from the merger with RiceX and the continued success of the sale of its nutraceutical through direct to consumer marketing during quarter ended December 31, 2005.
NutraCea (OTCBB: NTRZ) - NutraCea is a leader in stabilized rice bran nutrient research and dietary supplement development. Through it's wholly owned subsidiary RiceX, the company manufacturers as well as distributes products and food ingredients made from Rice Bran through its proprietary technology and processes. The Company has developed intellectual property to create a range of proprietary product formulations, delivery systems and whole food nutrition products. NutraCea's proprietary technology enables the creation of food and nutrition products from rice bran, normally a wasted by- product of standard rice processing. In addition to its whole foods products, NutraCea develops families of health-promoting "nutraceuticals," including natural arthritic relief and cholesterol-lowering products. More information can be found in the company's filings with the SEC and you can visit the NutraCea web site http://www.NutraCea.com.
CXIA...NEWS out Financials to come out next week!!
CURRENT REPORT ON FORM 8-K
COMMODORE APPLIED TECHNOLOGIES, INC.
August 16, 2006
ITEM 7.01 REGULATION FD DISCLOSURE
On August 14, 2006, Commodore Applied Technologies, Inc. (the
"Company") issued a press release announcing that it wholly owned subsidiary,
Commodore Advanced Sciences, Inc., has been awarded an Advanced Remediation
Demonstration Phase 1 contract by the Department of Energy's Environmental
Management Office for the separation of radioactive (surrogate) and RCRA heavy
metals from sludges and other waste matrices.
A copy of the press release is furnished as Exhibit 99.1.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(c) Exhibits.
99.1 Press Release dated August 14, 2006.
2
<PAGE>
The information contained in this report is being furnished pursuant to
Item 7.01, Regulation FD Disclosure, and Item 9.01, Financial Statements and
Exhibits.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this Current Report to be signed on its behalf by
the undersigned thereunto duly authorized.
COMMODORE APPLIED TECHNOLOGIES, INC.
Date: August 16, 2006 By: /s/ James M. DeAngelis
-------------------------
James M. DeAngelis
Senior Vice President and
Chief Financial Officer
3
<PAGE>
EXHIBIT INDEX
Exhibit No.
-----------
99.1 Press Release dated August 14, 2006 issued by Commodore
Applied Technologies, Inc.
4
</TEXT>
</DOCUMENT>
Exhibit 99.1
------------
AB
NEWS RELEASE
For release: Immediate
Contact: James M. DeAngelis - (212) 308-5800
Commodore Applied Technologies, Inc.
o Commodore Advanced Sciences wins Advanced Remediation
Demonstration Contract from the Department of Energy's Office of
Environmental Management
NEW YORK, NY - August 14, 2006 - Commodore Applied Technologies, Inc. (OTCBB:
CXIA), today announced that the Company's wholly owned subsidiary, Commodore
Advanced Sciences, Inc., (CASI) has been awarded an Advanced Remediation
Demonstration contract by the Department of Energy's Office of Environmental
Management (DOE-EM) for the Company's technology for the separation of
radioactive (surrogate) and RCRA heavy metals from sludges and other waste
matrices.
The DOE-EM awarded 12 contracts totaling $3.3 million to support the development
of technologies that have the potential to reduce cleanup costs and increase the
safety and efficiency of treating and disposing of various waste streams,
including radioactive waste at such sites as Hanford, Idaho, Savannah River, and
others.
- more -
<PAGE>
CASI DOE Contract
August 14, 2006
Page 2
CASI's Phase I contract will be performed over a six month period. Phase I
proposed activities include: laboratory/pilot-scale test results, developing a
technical approach for demonstration, scale-up and implementation schedule,
detailed system design, and a detailed cost estimate for implementation in Phase
II.
Chairman and CEO Mr. Shelby Brewer said: "Over the past several years, CASI has
focused on the delivery of innovative environmental services to the DOE-EM. This
recent contract award will allow us to expand our technology offerings to the
DOE-EM to assist them in their ongoing efforts to provide the safest, most cost
effective waste treatment processes for their facilities."
Commodore Applied Technologies, Inc. is a diverse technical solutions company
focused on high-end environmental markets. The Commodore family of companies
includes subsidiaries Commodore Solution Technologies and Commodore Advanced
Sciences. The Commodore companies provide technical services and patented
remediation technologies designed to treat hazardous waste from nuclear and
chemical sources. More information is available on the Commodore web site at
www.commodore.com.
- more -
<PAGE>
CASI DOE Contract
August 14, 2006
Page 3
This Press Release contains forward-looking statements that are based on our
current expectations, beliefs and assumptions about the industry and markets in
which Commodore Applied Technologies, Inc. and its subsidiaries operate. Such
forward-looking statements involve known and unknown risks, uncertainties, and
other factors that may cause Commodore's actual results to be materially
different from any future results expressed or implied by these statements.
Actual results may differ materially from what is expressed in these statements,
and no assurance can be given that Commodore can successfully implement its core
business strategy and improve future earnings.
The factors that may cause Commodore's actual results to differ from its
forward-looking statements include: Commodore's current critical need for
additional cash to sustain existing operations and meet ongoing existing
obligations and capital requirements; Commodore's ability to implement its
commercial waste processing operations, including obtaining commercial waste
processing contracts and processing waste under such contracts in a timely and
cost-effective manner; the timing and award of contracts by the U.S. Department
of Energy for the clean-up of waste sites administered by it; the acceptance and
implementation of Commodore's waste treatment technologies in the government and
commercial sectors; and other large technical support services projects. All
forward-looking statements are also expressly qualified in their entirety by the
cautionary statements included in Commodore's SEC filings, including its
quarterly reports on Form 10-Q and its annual report on Form 10-K.
###
DSCI...target 95 cents by a reputed analyst...seee below!!!
Derma Sciences, Inc., is an integrated manufacturer, marketer and supplier of a complete line of products for wound and skin care. Products fall into five categories: Advanced Wound Care, Traditional Wound Care, Burn Care, Skin Care and Bathing, and Specialty Securement and Closure Devices. With three wholly owned and operated manufacturing facilities in St. Louis, Toronto, and China, the Company offers contract manufacturing services for OEM or private label products.
The Company's wound care products consist of sprays, ointments and dressings for the management of chronic non-healing skin ulcerations, surgical incisions and burns. The Company's specialty fastener products consist of sterile pressure sensitive adhesive wound closure strips, pressure sensitive adhesive catheter fasteners and tubular net dressings. Their general purpose and specialized skincare products consist of body washes, shampoos, an incontinent wash, a moisture barrier ointment, skin moisturizers and lotions, hand washes and sanitizers and a hard surface disinfectant.
The Company's products are used primarily in hospitals, nursing homes, and home health settings. The Company's products include wound dressings, moisturizing lotions, hand soaps, incontinence care products, disinfectants, wound closure strips, and catheter/tubing securement devices. The Company markets its products principally through independent distributors servicing the long-term care, home health and acute care markets in the United States and select international markets.
DSCI released its financials last evening...
In short ....Derma Sciences Inc (DSCI) reported Q2 results ended June 2006. Q2 Revenues were $7.39M; +6.64% vs yr-ago; BEATING revenue consensus by +15.83%. Q2 EPS was 1c; 0.00% vs yr-ago; BEATING earnings consensus by +150.00%.
Also a little para from the SEC filing Aug 14 2006:
Prospective Assessment
The Company’s objective is to continue to grow sales and gross profit in 2006. Beginning in 2005, the Company expanded its product development efforts. As a result of these efforts, the Company expects to launch two new products in late 2006 and additional new product launches are anticipated in 2007. The April 2006 acquisition of the Western Medical business is anticipated to have a positive impact on the Company’s U.S. business going forward. Growth of the Company’s private label business is anticipated to accelerate in 2006 as the existing business continues to grow and new customers are brought on board. Plans are in place to better leverage existing opportunities in the Company’s basic and advanced wound care lines in the U.S. by working more closely with several key existing and potential new customers to increase business. In Canada, the exclusive distribution agreement represents an opportunity for sales growth in the near future.
The Company plans to build upon its recent success in the area of product cost savings. Higher throughput and improved operational efficiencies are expected to lower the Company’s overall internal cost of manufacturing going forward. Plans are in place to bring the manufacture of the Company’s wound closure-fastener line in-house during 2006 at a savings versus existing third party sourced product costs. The Company also anticipates realizing savings when it begins sterilizing its China sourced products in China in the second half of 2006. Subject to commodity driven cotton prices and foreign exchange changes, which are outside of the Company’s control, the Company anticipates continuing to building on its successful relationships in China to keep its basic wound care costs competitive.
Outstanding Shares: 20 Million Only!!!....on 8/14/2006
Float as of July 2006: 12 Million Only
Valuation REPORT by TAGLICHBROTHERS
http://www.taglichbrothers.com/equityuniverse/companies/dermasci/dermasci-07102006.pdf
They gave it a speculative buy with target of 0.95 ....by next JULY....which means at more than 20% rise..
Acquisitions- Last quarter company acquired, for $6.5 million, certain assets (mainly accounts receivable and inventory) and assumed trade payables from Western Medical, Inc., a closely held manufacturer of specialty medical textile compression, support and protective dressings. Western’s products will be combined with Derma Sciences’ wound care line. The company estimates roughly $1 million
The acquisition will add roughly $6.6 million (Western’s 2005 revenue) to Derma Sciences’ annual revenue, contributing an estimated $4.5 million to its 2006 sales. The Western acquisition should support an improvement in profitability; Western’s 2005 gross margin was roughly 39%, well above Derma Sciences’ gross margin for that year. Western’s 2005 pre-tax margin was reported at 11%, also well above Derma Sciences’ for 2005. None of Western’s manufacturing or administrative infrastructure was included in the transaction; those functions are being absorbed by Derma Sciences. With effective integration, most of the gross profit on Western’s revenue could eventually drop down to the operating income line, significantly improving profitability.